Skip to content

Exploration of the Long-Term Effects of Severe Burns on Patients' Blood and Urine Components, Inflammation Levels, and Renal Injury Markers, Along with Detection Methods

Exploration of the Long-Term Effects of Severe Burns on Patients' Blood and Urine Components, Inflammation Levels, and Renal Injury Markers, Along with Detection Methods

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121124
Enrollment
Unknown
Registered
2026-03-25
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary kidney disease following burns

Interventions

Severe Burn Cohort:None
Healthy Control Cohort:None

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Burn Patient Cohort: 1. Age at the time of burn injury: 18 to 60 years. 2. Sustained a severe burn requiring long-term hospitalization (Total Body Surface Area burned >50%, or >30% with severe injuries). 3. Enrolled within 1 year after hospital discharge. Healthy Control Cohort: 1. Age: 18 to 60 years.

Exclusion criteria

Exclusion criteria: For Burn Patients: 1. History of familial genetic disorders. 2. History of renal, cardiovascular, or psychiatric diseases. 3. History of severe infections or communicable diseases. 4. Prolonged residency in high-altitude regions. 5. Occupations involving exposure to thermal injury or radiation. 6. Non-compliance during the follow-up period. For Healthy Controls: 1. History of familial genetic disorders. 2. History of renal, cardiovascular, or psychiatric diseases. 3. History of severe infections or communicable diseases. 4. Long-term residency in high-altitude regions. 5. Occupations associated with thermal injury. 6. Non-compliance during the follow-up period.

Design outcomes

Primary

MeasureTime frame
Biomarker panel identified by high-throughput sequencing of blood and urine (proteomics and metabolomics);New-onset chronic kidney disease;End-stage renal disease (initiation of long-term maintenance renal replacement therapy or kidney transplantation);Other related events (cardiovascular events, readmission);

Countries

China

Contacts

Public ContactYang Guang

Peking University Shenzhen Hospital

yakoaka@foxmail.com+86 176 1276 2418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026